The partners of the EU-funded CardioReGenix held last week a two-day progress meeting to share the most recent updates on the project.
According to WHO estimates, 17.7 million people die each year from CVD, which constitutes more than 30% of all deaths worldwide. Recent advances in biomedical research improved our understanding of the molecular and cellular mechanisms of the disease and introduced efficient and safer gene therapy vectors for the development of next-generation advanced therapy medicinal products (ATMPs) for CVD.
CardioReGenix Horizon project partners are top-scientists in the area of cardiovascular research & treatment, and gene therapies. Our expert Laura Mendieta attended the meeting to update on Asphalion’s Regulatory developments. Asphalion is currently participating in the drafting of the IMPDs and IB documents for a future Clinical Trial to evaluate a Gene Therapy Investigational Medicinal Product for the treatment of Coronary Heart Disease.
For further information, you can contact us at: info@asphalion.com
